Shares of LifeVantage Corporation (LFVN) cratered 15.8% to $7.94 on June 2, erasing a large chunk of the explosive rally that lifted the stock from $5.61 in late May to $9.43 just a day earlier. With no fresh company news driving the selloff, the move looks like classic profit-taking after a speculative run — and it raises hard questions about whether this micro-cap health and wellness firm's fundamentals justify the recent excitement.

  • The Rally Had Thin Foundations to Begin With. Q3 fiscal 2026 revenue was $43.7 million, a decrease of 25.2% from the prior year, while net income per diluted share fell to $0.11 from $0.26 a year ago.

LifeVantage posted an EPS of $0.12 (adjusted), falling short of the forecasted $0.19, while actual revenue was below the expected $51.81 million. Despite those misses, the stock jumped 13.84% in aftermarket trading to $6.25 after earnings — a reaction driven more by speculative positioning than by the numbers. Today's reversal suggests that early buyers are cashing out.

  • A Bigger Dividend Sweetened the Deal, But Revenue Is Still Shrinking. The company declared a cash dividend of $0.05 per common share, an 11.1% increase from the previous quarterly dividend of $0.045.

The dividend will be paid on June 15, 2026 to shareholders of record at the close of business on June 1, 2026 — meaning today's sellers had already locked in their dividend eligibility. The payout is a shareholder-friendly gesture, but it's hard to grow dividends sustainably when the quarter's weakness came mainly from weaker sales of the company's GLP-1 weight-management system.

  • Management Is Steering Toward the Low End of a Disappointing Outlook. The company now anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be close to the lower end of its previously issued guidance range — that's $185 million in revenue and $0.60 EPS at the floor. Trailing twelve-month revenue sits at roughly $195 million, with a P/E of about 21x on $0.45 TTM earnings. Even after the drop, the valuation asks investors to bet on a turnaround that hasn't materialized.

  • A New CEO Brings Hope — But Not Until August. Terrence Moorehead was appointed as CEO effective August 5, 2026 , bringing more than 25 years of leadership experience in direct selling, having previously led Nature's Sunshine Products. Meanwhile, Lake Street downgraded the stock to Hold with a $5 price target after Q3 results. Investors betting on a quick recovery may have to wait longer than the stock's volatile swings suggest.